source
- BMS trial sees patient death, analysts say drug mechanism still viableBristol Myers Squibb is running a phase 3 study of an LPA1 inhibitor, admilparant, for idiopathic and progressive pulmonary fibrosis. A patient death was reported after the trial was amended to inc…
- AI system Claude decodes a whole genome in 30 minutes, sparking call for result standardsThe author, a Stanford physician‑scientist, used the AI model Claude to analyze his entire genome in roughly half an hour, at a cost of about five dollars. The rapid analysis produced a detailed re…